4,4'-(4-methyl-pyridine-2,6-diyl)-bis-morpholine | 51565-01-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4,4'-(4-methyl-pyridine-2,6-diyl)-bis-morpholine
• 英文别名: 4-(4-Methyl-6-morpholin-4-ylpyridin-2-yl)morpholine
• CAS: 51565-01-6
• 化学式: C₁₄H₂₁N₃O₂
• 分子量: 263.34
• InChiKey: WXSHOUVKKFFCJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  37.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• PYRIMIDINE DERIVATIVES 934
  申请人：Barlaam Bernard Christophe

  公开号：US20090023719A1

  公开（公告）日：2009-01-22

  A compound of formula (I) where one of A 1 , A 2 or A 3 is N, and the others are independently selected from CH or N; ring B is a fused 5 or 6-membered carbocyclic or heterocyclic which is optionally substituted as defined in the specification, and R 1 , R 2 , R 3 , R 4 , and n are as defined in the specification. The compounds are inhibitors of EphB4 or EphA2 and therefore may be useful in pharmaceutical compositions for the treatment of conditions such as cancer.

  式（I）的化合物，其中A1、A2或A3中的一个是N，其他的独立地选择自CH或N；环B是一个融合的5或6元碳环或杂环，可按规范中定义的方式取代，R1、R2、R3、R4和n如规范中定义。这些化合物是EphB4或EphA2的抑制剂，因此可能在用于治疗癌症等疾病的药物组合物中有用。
• NOVEL PYRIMIDINE DERIVATIVES - 816
  申请人：BARLAAM Bernard Christophe

  公开号：US20090036440A1

  公开（公告）日：2009-02-05

  The invention concerns pyrimidine compounds of Formula I, or a pharmaceutically acceptable salt thereof, where A 1 , A 2 A 3 , R 1 , n, R 2 , R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.

  本发明涉及公式I的嘧啶化合物或其药学上可接受的盐，其中A1，A2A3，R1，n，R2，R3和R4如描述中所定义。本发明还涉及制备这些化合物的方法，包含它们的制药组合物以及它们在制造抗增殖剂用药物中的应用，用于预防或治疗对EphB4激酶抑制敏感的肿瘤或其他增殖性疾病。
• TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES
  申请人：Cmiljanovic Vladimir

  公开号：US20110275762A1

  公开（公告）日：2011-11-10

  The invention relates to novel therapeutic agents and diagnostic probes. The invention also relates to phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor triazine-, pyrimidine- and pyridine-based compoundŝ Formula (I), their stereoisomers, geometric isomers, tautomers, solvates, metabolites, N-oxide derivatives, pharmaceutically acceptable salts, and prodrugs thereof compositions of the new compounds; either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, for treating disorders mediated by lipid kinases. •Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. (Formula I)

  本发明涉及新型治疗剂和诊断探针。本发明还涉及磷脂酰肌醇3-激酶（PI3K）和哺乳动物雷帕霉素靶蛋白酶（mTOR）抑制剂三嗪基、嘧啶基和吡啶基化合物̂公式（I），它们的立体异构体、几何异构体、互变异构体、溶剂化物、代谢物、N-氧化衍生物、药学上可接受的盐以及前药的组合物；新化合物的组合物，可以单独使用或与至少一种额外的治疗剂结合，与药学上可接受的载体；以及使用新化合物的方法，可以单独使用或与至少一种额外的治疗剂结合，用于治疗由脂质激酶介导的疾病。公开了使用公式（I）化合物的方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗这种疾病或相关病理条件。(公式I)
• US7718653B2
  申请人：——

  公开号：US7718653B2

  公开（公告）日：2010-05-18
• US8921361B2
  申请人：——

  公开号：US8921361B2

  公开（公告）日：2014-12-30